Literature DB >> 23153322

Salivary gland function 5 years after radioactive iodine ablation in patients with differentiated thyroid cancer: direct comparison of pre- and postablation scintigraphies and their relation to xerostomia symptoms.

Shin Young Jeong1, Hae Won Kim, Sang-Woo Lee, Byeong-Cheol Ahn, Jaetae Lee.   

Abstract

BACKGROUND: Chronic sialadenitis is one of the most frequent chronic complications after radioactive iodine (RAI) therapy for thyroid cancer. To evaluate the long-term effects of RAI ablation on salivary gland function, we investigated scintigraphic changes in salivary glands by direct comparison of two salivary gland scintigraphies (SGSs) taken before and at 5 years after an RAI ablation.
METHODS: SGS was performed just before RAI ablation (pre-SGS) and ∼5 years after RAI ablation (F/U SGS) in 213 subjects who underwent thyroidectomy for thyroid cancer. The uptake score (U score) was graded, and the ejection fraction (EF) was quantified for the parotid and submandibular glands at pre-SGS and F/U SGS. Changes in salivary gland function were graded as mild, moderate, or severe according to the differences in U score and EF between the two SGSs. Xerostomia was assessed and compared with the SGS findings.
RESULTS: Worsening of the U score was observed in 182 of 852 salivary glands (total: 21.3%; mild: 4.2%, moderate: 7.4%, severe: 9.7%), and 47.4% of the patients had a worsening U score for at least one of four salivary glands. A decrease in EF was observed in 173 of 852 salivary glands (total: 20.3%; mild: 5.4%, moderate: 6.8%, severe: 8.1%), and 43.7% of the patients experienced a decrease in the EF of at least one of the four salivary glands. Bilateral parotid gland dysfunction was the most commonly observed condition. Thirty-five (16.4%) patients complained of xerostomia at 5 years after RAI ablation. Scintigraphic changes in salivary gland function and xerostomia were more common in patients receiving 5.55 GBq, compared with 3.7 GBq. Xerostomia was more common in patients with submandibular gland dysfunction than those with parotid gland dysfunction (68.8% vs. 33.3%, p<0.05). The number of dysfunctional salivary glands was correlated with xerostomia (p<0.01).
CONCLUSION: About 20% of the salivary glands were dysfunctional on SGS 5 years after a single RAI ablation, especially in patients who received higher doses of RAI. While parotid glands are more susceptible to (131)I-related damage, xerostomia was more associated with submandibular gland dysfunction and the prevalence of dysfunctional salivary glands.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23153322      PMCID: PMC3643252          DOI: 10.1089/thy.2012.0106

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.568


  23 in total

1.  Radiation apoptosis of serous acinar cells of salivary and lacrimal glands.

Authors:  L C Stephens; T E Schultheiss; R E Price; K K Ang; L J Peters
Journal:  Cancer       Date:  1991-03-15       Impact factor: 6.860

2.  Quantification of salivary gland function in thyroid cancer patients treated with radioiodine.

Authors:  B L Malpani; A M Samuel; S Ray
Journal:  Int J Radiat Oncol Biol Phys       Date:  1996-06-01       Impact factor: 7.038

3.  Quantitative salivary gland scintigraphy in the diagnosis of parenchymal damage after treatment with radioiodine.

Authors:  K H Bohuslavizki; W Brenner; S Lassmann; S Tinnemeyer; G Tönshoff; C Sippel; H Wolf; M Clausen; E Henze
Journal:  Nucl Med Commun       Date:  1996-08       Impact factor: 1.690

4.  Physiological factors affecting salivary flow rate, oral sugar clearance, and the sensation of dry mouth in man.

Authors:  C Dawes
Journal:  J Dent Res       Date:  1987-02       Impact factor: 6.116

5.  Xerostomia in Sjögren's syndrome. Evaluation by sequential salivary scintigraphy.

Authors:  G L Schall; L G Anderson; R O Wolf; J R Herdt; T M Tarpley; N A Cummings; L S Zeiger; N Talal
Journal:  JAMA       Date:  1971-06-28       Impact factor: 56.272

6.  Short-term hazards of low-dose radioiodine ablation therapy in postsurgical thyroid cancer patients.

Authors:  W Y Lin; Y Y Shen; S J Wang
Journal:  Clin Nucl Med       Date:  1996-10       Impact factor: 7.794

7.  Salivary and lacrimal gland involvement in a patient who had undergone a thyroidectomy and was treated with radioiodine for thyroid cancer.

Authors:  A Markitziu; J Lustmann; B Uzieli; Y Krausz; R Chisin
Journal:  Oral Surg Oral Med Oral Pathol       Date:  1993-03

8.  Determination of variation of stimulated salivary flow rates.

Authors:  E M Ghezzi; L A Lange; J A Ship
Journal:  J Dent Res       Date:  2000-11       Impact factor: 6.116

9.  Salivary and lacrimal gland dysfunction (sicca syndrome) after radioiodine therapy.

Authors:  R Solans; J A Bosch; P Galofré; F Porta; J Roselló; A Selva-O'Callagan; M Vilardell
Journal:  J Nucl Med       Date:  2001-05       Impact factor: 10.057

10.  The results of various modalities of treatment of well differentiated thyroid carcinomas: a retrospective review of 1599 patients.

Authors:  N A Samaan; P N Schultz; R C Hickey; H Goepfert; T P Haynie; D A Johnston; N G Ordonez
Journal:  J Clin Endocrinol Metab       Date:  1992-09       Impact factor: 5.958

View more
  45 in total

1.  The 68Ga/177Lu theragnostic concept in PSMA targeting of castration-resistant prostate cancer: correlation of SUVmax values and absorbed dose estimates.

Authors:  Lorenza Scarpa; Sabine Buxbaum; Dorota Kendler; Katharina Fink; Jasmin Bektic; Leonhard Gruber; Clemens Decristoforo; Christian Uprimny; Peter Lukas; Wolfgang Horninger; Irene Virgolini
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-01-12       Impact factor: 9.236

2.  Risk Factors for Cardiovascular Disease Among Thyroid Cancer Survivors: Findings From the Utah Cancer Survivors Study.

Authors:  Jihye Park; Brenna E Blackburn; Patricia A Ganz; Kerry Rowe; John Snyder; Yuan Wan; Vikrant Deshmukh; Michael Newman; Alison Fraser; Ken Smith; Kim Herget; Anne C Kirchhoff; Dev Abraham; Jaewhan Kim; Marcus Monroe; Mia Hashibe
Journal:  J Clin Endocrinol Metab       Date:  2018-07-01       Impact factor: 5.958

3.  Reduction of Salivary Gland Damage During Radioiodine Therapy for Differentiated Thyroid Cancers.

Authors:  Byeong-Cheol Ahn
Journal:  Nucl Med Mol Imaging       Date:  2020-05-12

4.  First-in-human study of 177Lu-EB-PSMA-617 in patients with metastatic castration-resistant prostate cancer.

Authors:  Jie Zang; Xinrong Fan; Hao Wang; Qingxing Liu; Jingnan Wang; Hui Li; Fang Li; Orit Jacobson; Gang Niu; Zhaohui Zhu; Xiaoyuan Chen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-08-08       Impact factor: 9.236

5.  Aging-Related Disease Risks among Young Thyroid Cancer Survivors.

Authors:  Brenna E Blackburn; Patricia A Ganz; Kerry Rowe; John Snyder; Yuan Wan; Vikrant Deshmukh; Michael Newman; Alison Fraser; Ken Smith; Kimberly Herget; Jaewhan Kim; Anne C Kirchhoff; Christina Porucznik; Heidi Hanson; Marcus Monroe; Mia Hashibe
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2017-11-22       Impact factor: 4.254

6.  Looking under the hood of "the Cadillac of cancers:" radioactive iodine-related craniofacial side effects among patients with thyroid cancer.

Authors:  Samantha A Diamond-Rossi; Jacqueline Jonklaas; Roxanne E Jensen; Charlene Kuo; Selma Stearns; Giuseppe Esposito; Bruce J Davidson; George Luta; Gary Bloom; Kristi D Graves
Journal:  J Cancer Surviv       Date:  2020-06-06       Impact factor: 4.442

7.  Risk Factors of 131I-Induced Salivary Gland Damage in Thyroid Cancer Patients.

Authors:  Brynn Hollingsworth; Leigha Senter; Xiaoli Zhang; Guy N Brock; Wael Jarjour; Rebecca Nagy; Pamela Brock; Kevin R Coombes; Richard T Kloos; Matthew D Ringel; Jennifer Sipos; Ilene Lattimer; Ricardo Carrau; Sissy M Jhiang
Journal:  J Clin Endocrinol Metab       Date:  2016-08-17       Impact factor: 5.958

8.  Assessment of Salivary Gland Function Using Salivary Scintigraphy in Pre and Post Radioactive Iodine Therapy in Diagnosed Thyroid Carcinoma Patients.

Authors:  Raj Kumar Badam; Jyotsna Suram; Dara Balaji Gandhi Babu; Shefali Waghray; Rahul Marshal; Sharath Chandra Bontha; Reddy Lavanya; Sudheer Kanth
Journal:  J Clin Diagn Res       Date:  2016-01-01

9.  Nasal symptoms after radioiodine therapy: a rarely described side effect with similar frequency to lacrimal dysfunction.

Authors:  Jacqueline Jonklaas
Journal:  Thyroid       Date:  2014-12       Impact factor: 6.568

10.  Pre-therapeutic dosimetry of normal organs and tissues of (177)Lu-PSMA-617 prostate-specific membrane antigen (PSMA) inhibitor in patients with castration-resistant prostate cancer.

Authors:  Levent Kabasakal; Mohammad AbuQbeitah; Aslan Aygün; Nami Yeyin; Meltem Ocak; Emre Demirci; Turkay Toklu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-07-31       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.